Literature DB >> 17393386

On watching the watchers: IDO and type I/II IFN.

Paolo Puccetti1.   

Abstract

A series of recent studies, including an article in this issue of the European Journal of Immunology, have demonstrated that the immunoregulatory pathway of tryptophan catabolism, initiated by the enzyme indoleamine 2,3-dioxygenase (IDO), not only represents an effector mechanism of peripheral tolerance, but is also a critical participant in the promotion of an optimally protective immune response balanced between inflammation and tolerance. Although subjected to transcriptional regulation by type I/II IFN, IDO is itself required for the production of type I IFN in response to B7 signaling in CD19(+) DC. Such a bidirectional feedback loop could be part of an integrated response for preventing excessive inflammation and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393386     DOI: 10.1002/eji.200737184

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  29 in total

1.  Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity.

Authors:  Jamie L Harden; Tao Gu; Mehmet O Kilinc; Rachael B Rowswell-Turner; Lauren P Virtuoso; Nejat K Egilmez
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  Hypoxia abrogates antichlamydial properties of IFN-γ in human fallopian tube cells in vitro and ex vivo.

Authors:  Anna Roth; Peter König; Ger van Zandbergen; Matthias Klinger; Thomas Hellwig-Bürgel; Walter Däubener; Michael K Bohlmann; Jan Rupp
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

3.  Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype.

Authors:  Olivier Manches; Melissa Victoria Fernandez; Joel Plumas; Laurence Chaperot; Nina Bhardwaj
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-09       Impact factor: 11.205

4.  Indoleamine 2,3-dioxygenase (IDO) induced by Leishmania infection of human dendritic cells.

Authors:  M J Donovan; V Tripathi; M A Favila; N S Geraci; M C Lange; W Ballhorn; M A McDowell
Journal:  Parasite Immunol       Date:  2012-10       Impact factor: 2.280

5.  Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.

Authors:  Koyo Higashitani; Tatsuya Kanto; Shoko Kuroda; Sachiyo Yoshio; Tokuhiro Matsubara; Naruyasu Kakita; Tsugiko Oze; Masanori Miyazaki; Mitsuru Sakakibara; Naoki Hiramatsu; Eiji Mita; Yasuharu Imai; Akinori Kasahara; Alato Okuno; Osamu Takikawa; Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2012-09-14       Impact factor: 7.527

6.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells.

Authors:  Maria T Pallotta; Ciriana Orabona; Claudia Volpi; Carmine Vacca; Maria L Belladonna; Roberta Bianchi; Giuseppe Servillo; Cinzia Brunacci; Mario Calvitti; Silvio Bicciato; Emilia M C Mazza; Louis Boon; Fabio Grassi; Maria C Fioretti; Francesca Fallarino; Paolo Puccetti; Ursula Grohmann
Journal:  Nat Immunol       Date:  2011-07-31       Impact factor: 25.606

Review 7.  IDO: a double-edged sword for T(H)1/T(H)2 regulation.

Authors:  Hui Xu; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  Immunol Lett       Date:  2008-09-29       Impact factor: 3.685

Review 8.  Type I interferon: friend or foe?

Authors:  Giorgio Trinchieri
Journal:  J Exp Med       Date:  2010-09-13       Impact factor: 14.307

Review 9.  Immune-mediated animal models of Tourette syndrome.

Authors:  Mady Hornig; W Ian Lipkin
Journal:  Neurosci Biobehav Rev       Date:  2013-01-10       Impact factor: 8.989

10.  Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function.

Authors:  Aniuska Becerra; Rajas V Warke; Kris Xhaja; Barbara Evans; James Evans; Katherine Martin; Norma de Bosch; Alan L Rothman; Irene Bosch
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.